June 30 (Bloomberg) -- Roche Holding AG said the European Commission extended the Avastin metastatic breast cancer label to include combination with Xeloda, according to an e-mailed statement today.
To contact the editor responsible for this story: Simone Meier at smeier@bloomberg.net